Recent Finacing
Recent Raise
Bioxytran is a Boston-based clinical-stage biotechnology company developing Prolectin-M, an oral Galectin Antagonist antiviral, and advancing dosage optimization trials for COVID-19 alongside pulmonary fibrosis and stroke programs.
